Drug name - Xeglyze
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9839631 | DR REDDYS LABS SA | Methods and compositions for controlling ectoparasites |
Jul, 2024
(1 year, 7 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8212038 | DR REDDYS LABS SA | Methods and compositions for controlling ectoparasites |
Jul, 2024
(1 year, 7 months from now) | |
| US9357783 | DR REDDYS LABS SA | Methods and compositions for controlling ectoparasites |
Jul, 2024
(1 year, 7 months from now) | |
| US7812163 | DR REDDYS LABS SA | Methods and compositions for controlling ectoparasites |
Oct, 2026
(3 years from now) | |
| US10292389 | DR REDDYS LABS SA | Pediculicidal composition |
Dec, 2034
(12 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jul 24, 2025 |
Drugs and Companies using ABAMETAPIR ingredient
Market Authorisation Date: 24 July, 2020
Treatment: Topical treatment of head lice infestation in patients 6 months of age and older
Dosage: LOTION;TOPICAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 0.74% | LOTION;TOPICAL | Discontinued |
availability in other generic markets.
Click on the highlighted region to filter.